Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Myeloid 1Lymphoid 1

Conditions

Burkitt Lymphoma 11Precursor Cell Lymphoblastic Leukemia-Lymphoma 5Leukemia, Biphenotypic, Acute 5Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 3Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 3Lymphoma, Extranodal NK-T-Cell 2Leukemia, Myeloid, Acute 2Sarcoma, Myeloid 1Recurrence 1Lymphohistiocytosis, Hemophagocytic 1Down Syndrome 1

Interventions

pegaspargase 1Methylprednisolone 1Etoposide 1Asparaginase 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lymphohistiocytosis, Hemophagocytic × Asparaginase × 90 days × Clear all
NCT07525466 2026-04-13

Combination of Mitoxantrone Liposome and Etoposide, Dexamethasone, Pegaspargase and Golidocitinib (MEPL-G) in the Treatment of NK/T-cell Lymphoma Associated Hemophagocytic Lymphohistiocytosis (NKTCL-HLH)

Beijing Tongren Hospital

Phase 1/2 Recruiting
25 enrolled
LymphoidMyeloid

Lymphohistiocytosis, Hemophagocytic, Lymphoma, Extranodal NK-T-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡